Spinal cord hemangioblastomas in von Hippel-Lindau disease.

IF 3.7 Q1 CLINICAL NEUROLOGY
Neuro-oncology advances Pub Date : 2024-02-13 eCollection Date: 2024-10-01 DOI:10.1093/noajnl/vdad153
Daniel C Kreatsoulas, Russell R Lonser
{"title":"Spinal cord hemangioblastomas in von Hippel-Lindau disease.","authors":"Daniel C Kreatsoulas, Russell R Lonser","doi":"10.1093/noajnl/vdad153","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>von Hippel-Lindau disease (VHL) is an autosomal dominant familial neoplasia syndrome. The most common manifestation of VHL is central nervous system hemangioblastomas. VHL patients will often develop multiple hemangioblastomas along their craniospinal axis over their lifetime. Spinal cord hemangioblastomas account for nearly half of all nervous system hemangioblastomas in VHL.</p><p><strong>Methods: </strong>The authors conducted a literature review and summation of available articles on spinal cord hemangioblastomas associated with VHL.</p><p><strong>Results: </strong>The embryological origins, epidemiology, natural history, surgical outcomes, nonsurgical treatments, and future directions in spinal cord hemangioblastomas are discussed.</p><p><strong>Conclusions: </strong>Hemangioblastomas in VHL are optimally managed with a multidisciplinary approach that includes surgical resection of symptomatic lesions. Novel treatments are gaining traction, but must be studied further for efficacy and safety.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"6 Suppl 3","pages":"iii66-iii72"},"PeriodicalIF":3.7000,"publicationDate":"2024-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485647/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology advances","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/noajnl/vdad153","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: von Hippel-Lindau disease (VHL) is an autosomal dominant familial neoplasia syndrome. The most common manifestation of VHL is central nervous system hemangioblastomas. VHL patients will often develop multiple hemangioblastomas along their craniospinal axis over their lifetime. Spinal cord hemangioblastomas account for nearly half of all nervous system hemangioblastomas in VHL.

Methods: The authors conducted a literature review and summation of available articles on spinal cord hemangioblastomas associated with VHL.

Results: The embryological origins, epidemiology, natural history, surgical outcomes, nonsurgical treatments, and future directions in spinal cord hemangioblastomas are discussed.

Conclusions: Hemangioblastomas in VHL are optimally managed with a multidisciplinary approach that includes surgical resection of symptomatic lesions. Novel treatments are gaining traction, but must be studied further for efficacy and safety.

von Hippel-Lindau病的脊髓血管母细胞瘤。
背景:冯-希佩尔-林道病(VHL)是一种常染色体显性家族性肿瘤综合征。VHL 最常见的表现是中枢神经系统血管母细胞瘤。VHL 患者在一生中往往会沿着颅脊轴长出多个血管母细胞瘤。脊髓血管母细胞瘤占 VHL 神经系统血管母细胞瘤的近一半:作者对与VHL相关的脊髓血管母细胞瘤进行了文献综述和总结:结果:讨论了脊髓血管母细胞瘤的胚胎起源、流行病学、自然史、手术结果、非手术治疗和未来发展方向:结论:VHL患者的血管母细胞瘤可通过多学科方法得到最佳治疗,包括对有症状的病灶进行手术切除。新型治疗方法正逐渐受到重视,但其疗效和安全性还需进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.20
自引率
0.00%
发文量
0
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信